U.S. markets open in 7 hours 37 minutes

CNS Pharmaceuticals, Inc. (CNSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7900-0.0100 (-0.56%)
At close: 3:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close1.8000
Open1.7500
Bid0.0000 x 900
Ask0.0000 x 2200
Day's Range1.7500 - 1.8400
52 Week Range1.2580 - 5.6900
Volume15,696
Avg. Volume92,786
Market Cap29.807M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateMar 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV
    PR Newswire

    CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment of "Behind the Mystery" focused on glioblastoma from The Balancing Act airing on Lifetime TV. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of the Scientific Advisory Board of CNS Pharmaceuticals. A re-airing of the segment is planned for October 23, 2020.

  • CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe
    PR Newswire

    CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company's European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

  • CNS Pharmaceuticals Achieves Critical Manufacturing Milestone
    PR Newswire

    CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company's GMP manufacturer partner NCK A/S, received a Certificate of Analysis (CoA) for its Active Pharma Ingredient (API), clearing it for use in the production of Berubicin.